Experience
AstraZeneca AB
Zydus Pharmaceuticals (USA) Inc.
Finnegan served as IP counsel to AstraZeneca in this Hatch-Waxman litigation involving patents protecting FARXIGA®, one of AstraZeneca’s billion dollar a year drugs. FARXIGA® is part of a new class of diabetes drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors and is currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Nearly 30 million Americans have type 2 diabetes, and the patents involved in the litigation provide over seven years of patent protection for this important drug. FARXIGA® was also approved to reduce the risk of declining kidney function, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease with or without diabetes, a first in the SGLT2 class of diabetes drugs. After a bench trial, Judge Andrews ruled that the defendant failed to prove that any of the patent claims at issue were invalid due to obviousness, resulting in a complete win for our client.
AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc., 1:18-cv-00664, D. Del., Judge Andrews
AstraZeneca AB v. Lannett Holdings, Inc.
AstraZeneca AB
AstraZeneca Pharmaceuticals LP, Shionogi Co. v. Watson Pharmaceuticals, Inc.
AstraZeneca Pharmaceuticals LP; Shionogi Co.
Lannett Holdings, Inc. v. AstraZeneca AB
AstraZeneca AB
Medicis Pharmaceutical Corp. v. Zydus Pharmaceuticals (USA) Inc.
Medicis Pharmaceutical Corp.
Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc.
Pronova Biopharma Norge AS
AstraZeneca LP v. SigmaPharm Laboratories
AstraZeneca LP
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.
Biogen International GmbH
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.